Viridian Therapeutics Inc.
VRDN | NASDAQ
$21.79
+$0.21 (+0.97%)
Sep 22, 2026, 12:30 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 70.85M | 302K | 314K | 1.77M | 2.96M | 1.05M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 28.3M |
Gross Profit | 70.85M | 302K | 314K | 1.77M | 2.96M | -27.25M |
Operating Income | -363.4M | -299.04M | -254.45M | -134.3M | -79.73M | -110.38M |
Interest Income | 27.4M | 32.13M | 18.56M | 4.92M | 318K | 173K |
Pretax Income | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M |
Net Income | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M |
Selling & General & Admin | 95.32M | 61.08M | 95M | 35.18M | 25.81M | 13.27M |
Research & Development | 338.93M | 238.25M | 159.77M | 100.89M | 56.89M | 28.3M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 41.56M |
Operating Expenses | 434.24M | 299.34M | 254.76M | 136.08M | 82.69M | 83.13M |
Interest Expense | 4.95M | 3.05M | 1.85M | 486K | 3K | 508K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 434.24M | 299.34M | 254.76M | 136.08M | 82.69M | 111.43M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 84.8M | 67.89M | 44.76M | 32.09M | 11.92M | 3.56M |
Shares Outstanding (Diluted) | 84.8M | 67.89M | 44.76M | 32.09M | 11.92M | 3.56M |
EPS (Basic) | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 |
EPS (Diluted) | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 |
EBITDA | -337.19M | -265.66M | -235.37M | -129.13M | -79.29M | -40.28M |
EBIT | -337.65M | -266.9M | -235.89M | -129.39M | -79.41M | -40.52M |
Depreciation & Amortization | 460K | 1.24M | 522K | 255K | 120K | 239K |
Add to Watchlist
Select watchlists to add or remove VRDN